{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T14:36:56Z","timestamp":1770993416312,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.dld.2023.05.017","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T08:47:05Z","timestamp":1686646025000},"page":"997-1000","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["A pragmatic strategy for the screening and treatment of portal hypertension in patients needing systemic treatment for advanced hepatocellular carcinoma"],"prefix":"10.1016","volume":"55","author":[{"given":"Fabio","family":"Piscaglia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"La Mura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1142-8585","authenticated-orcid":false,"given":"Federico","family":"Ravaioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2023.05.017_bib0001","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII \u2013 renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2023.05.017_bib0002","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/hep.27431","article-title":"Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis","volume":"61","author":"Berzigotti","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2023.05.017_bib0003","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1177\/2050640615615041","article-title":"Determinants of esophageal varices bleeding in patients with advanced hepatocellular carcinoma treated with sorafenib","volume":"4","author":"Iavarone","year":"2016","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.dld.2023.05.017_bib0004","doi-asserted-by":"crossref","first-page":"6654","DOI":"10.3390\/jcm11226654","article-title":"Child-Pugh score, MELD score and Glasgow Blatchford score to predict the in-hospital outcome of portal hypertensive patients presenting with upper gastrointestinal bleeding: an experience from tertiary healthcare system","volume":"11","author":"Jamil","year":"2022","journal-title":"JCM"},{"key":"10.1016\/j.dld.2023.05.017_bib0005","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"de Franchis","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2023.05.017_bib0006","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/jgh.12341","article-title":"Predictors of in-hospital mortality after acute variceal bleeding in patients with hepatocellular carcinoma and concurrent main portal vein thrombosis","volume":"29","author":"Han","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2023.05.017_bib0007","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/liv.13945","article-title":"How to clarify the Baveno VI criteria for ruling out varices needing treatment by noninvasive tests","volume":"39","author":"Cal\u00e8s","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2023.05.017_bib0008","article-title":"Beta-blockers in the era of precision medicine in patients with cirrhosis","author":"Albillos","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2023.05.017_bib0009","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jhep.2021.07.004","article-title":"Systemic treatment of hepatocellular carcinoma: an EASL position paper","volume":"75","author":"Bruix","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2023.05.017_bib0010","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2023.05.017_bib0011","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1053\/j.gastro.2021.12.276","article-title":"AGA clinical practice guideline on systemic therapy for hepatocellular carcinoma","volume":"162","author":"Su","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2023.05.017_bib0012","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma: heimbach et\u00a0al","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2023.05.017_bib0013","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.dld.2023.05.017_bib0014","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/j.dld.2023.01.133","article-title":"Incidence and risk factors of esophagogastric varices bleeding in cirrhotic patients with advanced hepatocellular carcinoma treated with lenvatinib","volume":"55","author":"Lavarone","year":"2023","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2023.05.017_bib0015","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/hep.32468","article-title":"Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and child-pugh A and B cirrhosis: a real-world study","volume":"76","author":"D'Alessio","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2023.05.017_bib0016","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jhep.2020.11.026","article-title":"Systemic treatment of HCC in special populations","volume":"74","author":"Rimassa","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2023.05.017_bib0017","doi-asserted-by":"crossref","DOI":"10.14309\/ajg.0000000000001887","article-title":"A combined Baveno VII and spleen stiffness algorithm to improve the non-invasive diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease","author":"Dajti","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2023.05.017_bib0018","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.dld.2018.12.013","article-title":"Are the expanded Baveno VI criteria really safe to screen compensated cirrhotic patients for high-risk varices?","volume":"51","author":"Dajti","year":"2019","journal-title":"Digest Liver Dis"},{"key":"10.1016\/j.dld.2023.05.017_bib0019","doi-asserted-by":"crossref","DOI":"10.1111\/apt.17380","article-title":"Review article: controversies surrounding the use of carvedilol and other beta blockers in the management of portal hypertension and cirrhosis","author":"Gillespie","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2023.05.017_bib0020","article-title":"Treatment of portal hypertension in patients with HCC in the era of Baveno VII","author":"Thabut","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2023.05.017_bib0021","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15092480","article-title":"Baveno VII criteria is an accurate risk stratification tool to predict high-risk varices requiring intervention and hepatic events in patients with advanced hepatocellular carcinoma","volume":"15","author":"Wu","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.dld.2023.05.017_bib0022","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1055\/s-0031-1281856","article-title":"Ultrasound in portal hypertension\u2013part 1","volume":"32","author":"Berzigotti","year":"2011","journal-title":"Ultraschall Med"},{"key":"10.1016\/j.dld.2023.05.017_bib0023","first-page":"1","article-title":"Ultrasound in portal hypertension\u2013part 2\u2013and EFSUMB recommendations for the performance and reporting of ultrasound examinations in portal hypertension","volume":"33","author":"Berzigotti","year":"2012","journal-title":"Ultraschall Med"},{"key":"10.1016\/j.dld.2023.05.017_bib0024","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/hep.28368","article-title":"Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study","volume":"63","author":"Piscaglia","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2023.05.017_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2022.102059","article-title":"Screening and management of portal hypertension in advanced hepatocellular carcinoma: a French practice survey","volume":"47","author":"Allaire","year":"2023","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.dld.2023.05.017_bib0026","doi-asserted-by":"crossref","DOI":"10.1111\/liv.15559","article-title":"Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension","author":"Turco","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2023.05.017_bib0027","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/apt.16490","article-title":"Nonselective beta-blockers are associated with a lower risk of hepatocellular carcinoma among cirrhotic patients in the United States","volume":"54","author":"Wijarnpreecha","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2023.05.017_bib0028","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jhep.2022.02.004","article-title":"Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma","volume":"77","author":"Ollivier-Hourmand","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2023.05.017_bib0029","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1002\/hep.26629","article-title":"Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study","volume":"58","author":"Ripoll","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2023.05.017_bib0030","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.7150\/jca.30434","article-title":"Prophylactic endoscopic therapy for variceal bleeding in patients with hepatocellular carcinoma","volume":"10","author":"Chen","year":"2019","journal-title":"J Cancer"},{"key":"10.1016\/j.dld.2023.05.017_bib0031","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1111\/liv.15458","article-title":"A history of variceal bleeding is associated with further bleeding under atezolizumab\u2013bevacizumab in patients with HCC","volume":"42","author":"Larrey","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2023.05.017_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2023.02.023","article-title":"Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: the IMPORTAL competing-risk meta-analysis","author":"Guerrero","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2023.05.017_bib0033","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2147\/JHC.S390777","article-title":"Presence of hepatocellular carcinoma does not affect course and response to anticoagulation of bland portal vein thrombosis in cirrhotic patients","volume":"10","author":"Benevento","year":"2023","journal-title":"JHC"},{"key":"10.1016\/j.dld.2023.05.017_bib0034","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00535-019-01642-1","article-title":"REFLECT\u2014a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset","volume":"55","author":"Yamashita","year":"2020","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.dld.2023.05.017_bib0035","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2023.05.017_bib0036","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1111\/liv.14992","article-title":"Safety of direct oral anticoagulants in patients with advanced liver disease","volume":"41","author":"Semmler","year":"2021","journal-title":"Liver Int"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865823006266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865823006266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:22:08Z","timestamp":1761625328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865823006266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S1590865823006266"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2023.05.017","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A pragmatic strategy for the screening and treatment of portal hypertension in patients needing systemic treatment for advanced hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2023.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}